Cell Source Stock Net Income
| CLCS Stock | USD 0.90 0.01 1.12% |
As of the 4th of February, Cell Source shows the Mean Deviation of 4.51, risk adjusted performance of 0.1785, and Downside Deviation of 8.75. Cell Source technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices. Please confirm Cell Source downside deviation, jensen alpha, as well as the relationship between the Jensen Alpha and downside variance to decide if Cell Source is priced correctly, providing market reflects its regular price of 0.9 per share. Given that Cell Source is a hitting penny stock territory we recommend to closely look at its total risk alpha.
Cell Source's financial statements offer valuable quarterly and annual insights to potential investors, highlighting the company's current and historical financial position, overall management performance, and changes in financial standing over time. Key fundamentals influencing Cell Source's valuation are provided below:Cell Source does not presently have any fundamental signals for analysis. This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools. Cell |
Cell Source 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Cell Source's pink sheet what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Cell Source.
| 11/06/2025 |
| 02/04/2026 |
If you would invest 0.00 in Cell Source on November 6, 2025 and sell it all today you would earn a total of 0.00 from holding Cell Source or generate 0.0% return on investment in Cell Source over 90 days. Cell Source is related to or competes with Propanc Biopharma,, and Telescope Innovations. Cell Source, Inc., a biotechnology company, develops cell therapy treatments based on the management of immune tolerance More
Cell Source Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Cell Source's pink sheet current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Cell Source upside and downside potential and time the market with a certain degree of confidence.
| Downside Deviation | 8.75 | |||
| Information Ratio | 0.223 | |||
| Maximum Drawdown | 31.62 | |||
| Value At Risk | (9.09) | |||
| Potential Upside | 12.5 |
Cell Source Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Cell Source's investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Cell Source's standard deviation. In reality, there are many statistical measures that can use Cell Source historical prices to predict the future Cell Source's volatility.| Risk Adjusted Performance | 0.1785 | |||
| Jensen Alpha | 1.52 | |||
| Total Risk Alpha | 1.13 | |||
| Sortino Ratio | 0.1682 | |||
| Treynor Ratio | (60.09) |
Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Cell Source's price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Cell Source February 4, 2026 Technical Indicators
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | 0.1785 | |||
| Market Risk Adjusted Performance | (60.08) | |||
| Mean Deviation | 4.51 | |||
| Semi Deviation | 4.25 | |||
| Downside Deviation | 8.75 | |||
| Coefficient Of Variation | 432.78 | |||
| Standard Deviation | 6.6 | |||
| Variance | 43.51 | |||
| Information Ratio | 0.223 | |||
| Jensen Alpha | 1.52 | |||
| Total Risk Alpha | 1.13 | |||
| Sortino Ratio | 0.1682 | |||
| Treynor Ratio | (60.09) | |||
| Maximum Drawdown | 31.62 | |||
| Value At Risk | (9.09) | |||
| Potential Upside | 12.5 | |||
| Downside Variance | 76.48 | |||
| Semi Variance | 18.06 | |||
| Expected Short fall | (7.69) | |||
| Skewness | 0.4263 | |||
| Kurtosis | 2.19 |
Cell Source Backtested Returns
Cell Source is out of control given 3 months investment horizon. Cell Source secures Sharpe Ratio (or Efficiency) of 0.24, which signifies that the company had a 0.24 % return per unit of risk over the last 3 months. We were able to break down twenty-eight different technical indicators, which can help you to evaluate if expected returns of 1.63% are justified by taking the suggested risk. Use Cell Source Mean Deviation of 4.51, risk adjusted performance of 0.1785, and Downside Deviation of 8.75 to evaluate company specific risk that cannot be diversified away. Cell Source holds a performance score of 18 on a scale of zero to a hundred. The firm shows a Beta (market volatility) of -0.0252, which signifies not very significant fluctuations relative to the market. As returns on the market increase, returns on owning Cell Source are expected to decrease at a much lower rate. During the bear market, Cell Source is likely to outperform the market. Use Cell Source sortino ratio and the relationship between the downside variance and period momentum indicator , to analyze future returns on Cell Source.
Auto-correlation | 0.43 |
Average predictability
Cell Source has average predictability. Overlapping area represents the amount of predictability between Cell Source time series from 6th of November 2025 to 21st of December 2025 and 21st of December 2025 to 4th of February 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Cell Source price movement. The serial correlation of 0.43 indicates that just about 43.0% of current Cell Source price fluctuation can be explain by its past prices.
| Correlation Coefficient | 0.43 | |
| Spearman Rank Test | 0.29 | |
| Residual Average | 0.0 | |
| Price Variance | 0.03 |
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
| Competition |
Based on the recorded statements, Cell Source reported net income of (5.47 Million). This is 101.6% lower than that of the Healthcare sector and 107.81% lower than that of the Biotechnology industry. The net income for all United States stocks is 100.96% higher than that of the company.
Cell Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Cell Source's direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of Cell Source could also be used in its relative valuation, which is a method of valuing Cell Source by comparing valuation metrics of similar companies.Cell Source is currently under evaluation in net income category among its peers.
Cell Fundamentals
| Return On Asset | -3.78 | |||
| Current Valuation | 59.65 M | |||
| Shares Outstanding | 35.25 M | |||
| Shares Owned By Insiders | 32.13 % | |||
| Price To Earning | (3.28) X | |||
| EBITDA | (4.11 M) | |||
| Net Income | (5.47 M) | |||
| Cash And Equivalents | 93.09 K | |||
| Total Debt | 6.5 M | |||
| Debt To Equity | (1.04) % | |||
| Current Ratio | 0.03 X | |||
| Book Value Per Share | (0.34) X | |||
| Cash Flow From Operations | (3.38 M) | |||
| Earnings Per Share | (0.20) X | |||
| Beta | -64.41 | |||
| Market Capitalization | 10.61 M | |||
| Total Asset | 313.77 K | |||
| Retained Earnings | (21.7 M) | |||
| Working Capital | (7.79 M) | |||
| Current Asset | 213.56 K | |||
| Current Liabilities | 8 M | |||
| Net Asset | 313.77 K |
About Cell Source Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Cell Source's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Cell Source using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Cell Source based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Cell Pink Sheet Analysis
When running Cell Source's price analysis, check to measure Cell Source's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Cell Source is operating at the current time. Most of Cell Source's value examination focuses on studying past and present price action to predict the probability of Cell Source's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Cell Source's price. Additionally, you may evaluate how the addition of Cell Source to your portfolios can decrease your overall portfolio volatility.